Global /Japan /Healthcare /Drug Manufacturers - General /4578
chevron_leftBack
Otsuka Holdings Co., Ltd. logo

Otsuka Holdings Co., Ltd.

4578
TSE: 4578 Delayed
11,400JPY 2%
71.18 USD
As of 7 June 2026, Otsuka Holdings Co., Ltd. has a market cap of $36.84B USD, ranking #692 globally and #44 in Japan. It ranks #58 in the Healthcare sector, and #28 in the Drug Manufacturers - General industry.
Global Rank
692
Country Rank
44
Sector Rank
58
Industry Rank
28
Key Stats
Market Cap
$36.84BUSD
5.9T JPY
Enterprise Value
$35.07BUSD
5.62T JPY
Revenue (TTM)
$15.72BUSD
2.52T JPY
EBITDA (TTM)
$3.71BUSD
594.5B JPY
Net Income (TTM)
$2.35BUSD
376.5B JPY
EBITDA Margin
24%
Profit Margin
15%
PE Ratio
15.7
Forward PE
18.8
PS Ratio
2.3
PB Ratio
1.9
EV/EBITDA
8.9
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Makoto Inoue open_in_new
Employees
37,758
Founded
1921
Website
otsuka.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
2% 5.7% -1.9% 22% 34% 66%

News

Loading...

Markets

Exchange Ticker Price
Tokyo Stock Exchange
MIC: XTKS
PRIMARY
4578
大塚ホールディングス株式会社
ISIN: JP3188220002
Shares Out.:
527.307M1 Shares Float: 405.443M2
TV:
SA:
YF:
GF:
BA:
MS:
11,400 JPY
Mexican Bolsa
MIC: XMEX
4578 (4578/N)
大塚ホールディングス株式会社
ISIN: JP3188220002
Shares Out.:
528.131M1 Shares Float: 411.889M2
TV:
SA:
YF:
GF:
BA:
MS:
1,025.98 MXN
Frankfurt Stock Exchange
MIC: XFRA
OS1
大塚ホールディングス株式会社
ISIN: JP3188220002
TV:
SA:
YF:
GF:
BA:
OS1
MS:
60.00 EUR
Show all 5 markets
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Otsuka Holdings Co., Ltd.

Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, autoimmune space digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices. It also provides clinical testing, medical equipment and tools, food products, cosmetics, functional food products, chemical products, soft drinks, beverages, analytical and measurement equipment, nutritional products, vehicle headlight testers, synthetic resin molded products, paper products, quasi-drugs, household products, and packaging materials and electronic parts. In addition, it offers IT solutions; adhesive tapes; flaky titanate and compounds; infusion and clinical nutrition products; hydrazine; plant-based food products; reinsurance underwriting services; wine; stable isotopes; food supplements; software and services for management of mental healthcare systems; anticancer drugs; terracess; bio-pesticides; dietetic food products; spring and mineral water; and polyolefin foams. Further, it engages in the warehousing and transport, medical device operational management, shared service, environmental health management, and venture capital and incubation businesses; rental of medical devices and related products; purchase and sale of agricultural products; import and export trading business; tuberculosis research and development activities; rental of space and office businesses; manufacturing and development of xenotransplantation products; and processing and marketing of functional films, as well as planning, design, production, and construction of ceramic boards and arts, ceramic walls, reliefs, terracotta, ceramic OT and portraits, and ceramic sign boards; and operation of travel agency, and Hotel Ridge and California Table. The company was founded in 1921 and is headquartered in Chiyoda, Japan.

Similar Companies

Industry: Drug Manufacturers - General (Japan)
Name
Market Cap diff.
PE
$81.66B
13.07T JPY
122%
28.9
$52.21B
8.36T JPY
42%
75.1
$30.37B
4.86T JPY
-18%
16.2
$25.82B
4.13T JPY
-30%
14.2
$16.91B
2.71T JPY
-54%
13.9
$7.73B
1.24T JPY
-79%
18.4
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
2K%
38.1
JNJ
$547.28B
1K%
26.4
ABBV
$360.63B
879%
97.4
$324.68B
256.25B CHF
781%
19.9
AZN
$289.43B
215.59B GBP
686%
27.6
NOVN
$277.35B
218.9B CHF
653%
20.5
chevron_leftBack